Definitive

Appia Signs Letter Agreement to Acquire up to a 70% Interest in a Prospective Brazilian Rare Earths Ionic Clay Project

Retrieved on: 
Tuesday, March 7, 2023
Niobium, Neodymium, US, FSE, Tropical climate, PCH, Terbium, API, Dysprosium, Light, Metal, Date, Fission Uranium Corp., Canadian Securities Exchange, NSR, International joint venture, OEM, LTDA, CSE, Documentation, National instrument, Nature, Transaction, Temperature, REE, National Instrument 43-101, Definitive, Praseodymium, Joint venture, Interest, News, Metallurgy, Letter, Rare-earth element, Security (finance), NewCo, Appia

Appia is very excited to have entered into the Letter Agreement to secure this high potential property in Brazil.

Key Points: 
  • Appia is very excited to have entered into the Letter Agreement to secure this high potential property in Brazil.
  • A number of professional consultants with direct ionic clay expertise have been contacted to bring together a project team suited for this specialized project.
  • Appia will take the next 90 days to complete its due diligence on the properties prior to finalizing this option agreement.
  • "Ionic adsorption clays are the main source of the critical rare earth permanent magnet metals, dysprosium and terbium," stated Stephen Burega, President of Appia.

Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2022

Retrieved on: 
Thursday, February 23, 2023
EBITDA, Social media, ID, RNA, ATLA: All This Life Allows, Vol. 1, Definitive, Affiliation, RNA interference, Organization, Hospital, Eastern Time Zone, GAAP, Research, Publication, Therapy, Map, Atlas, Data, Physician, Data set, Health care, Food delivery, Cryptocurrency, Payment card, Pharmaceutical industry, Fine chemical, Mobile phone, Real estate, Bookkeeping, Security (finance), Medicaid, Medicare

FRAMINGHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2022. 

Key Points: 
  • FRAMINGHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2022.
  • Fourth Quarter 2022 Financial Highlights:
    Revenue was $60.6 million, an increase of 31% from $46.3 million in Q4 2021.
  • Full Year 2022 Financial Highlights:
    Revenue was $222.7 million for the year, an increase of 34% from $166.2 million for the full year 2021.
  • “Definitive Healthcare once again delivered in 2022 with a 34% year-over-year revenue growth rate and a 29% adjusted EBITDA margin – representing a Rule of 63 Performance.” said Robert Musslewhite, CEO of Definitive Healthcare.

Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

Retrieved on: 
Friday, February 17, 2023
DNA, B cell, Immune reconstitution inflammatory syndrome, Secondary malignant neoplasm, Stanford University School of Medicine, Pediatrics, Inborn errors of metabolism, Blood, Stanford University, FA, Patient, Safety, Infection, DNA repair, European Society for Primary Immunodeficiencies, IEWP, Penile ultrasonography, Bone marrow failure, Research, Therapy, Infertility, Risk, Graft-versus-host disease, Toxic epidermal necrolysis, End organ damage, MDS, Haematopoietic system, Mucositis, Transplant, CD117, Fanconi anemia, Allotransplantation, Definitive, Syndrome, Pharmaceutical industry, Dentistry, Jasper

The study is a Phase 1/2 clinical trial ( NCT04784052 ) utilizing briquilimab to treat FA patients in bone marrow failure requiring allogeneic transplant with non-sibling donors.

Key Points: 
  • The study is a Phase 1/2 clinical trial ( NCT04784052 ) utilizing briquilimab to treat FA patients in bone marrow failure requiring allogeneic transplant with non-sibling donors.
  • In the follow-up data series presented, 100% total donor chimerism was achieved through six months for the first patient and at three months for the second patient.
  • Briquilimab was cleared by day 9 after dosing in both patients and no treatment-related adverse events or toxicities were observed.
  • It is also the only proven treatment for the bone marrow failure that occurs in a majority of patients with FA.

Canada Silver Cobalt Finalizes Option Agreement for LCT Lithium Property near Power Metals Corp Case Lake Project

Retrieved on: 
Monday, February 6, 2023
NSR, National Instrument 43-101, FSE, South Tyrol Option Agreement, Power metal, National instrument, PGO, Smart contract, Acquisition, Option, Tantalum, Element, LCT, CCW, Environment, Definitive, Exercise, TSX Venture Exchange, Engineering, News, Lithium, Security (finance), Caesium, Property

The property package is approximately 240 km2 and is contiguous with Power Metals' Case Lake Lithium LCT property near Cochrane, Ontario.

Key Points: 
  • Coquitlam, British Columbia--(Newsfile Corp. - February 6, 2023) - Canada Silver Cobalt Works Inc. (TSXV: CCW) (OTCQB: CCWOF) (FSE: 4T9B) (the "Company" or "Canada Silver Cobalt") announces it has finalized and signed the Option Agreement to acquire a large prospective LCT Pegmatite land package (Lithium-Cesium-Tantalum) near Power Metals Case Lake Project.
  • The Company has strategically staked a large package surrounding both the claims provided by the Option Agreement and claims adjacent to the Power Metals Case Lake LCT Lithium project for a total holding of close to 240 square kilometres.
  • The Property and project will be focused on exploring the LCT potential in the area.
  • VP Exploration, commented, "The location, size, and proximity to existing lithium discoveries has our team excited to get started working on this property.

Definitive Healthcare introduces the Atlas Dataset

Retrieved on: 
Thursday, February 2, 2023
Marketing, Data science, Publication, Natural language processing, Atlas, Love, Hospital, Social media, Research, Tebenna inspirata, Intelligence, Internationalized domain name, Artificial intelligence, Definitive, Data set, Data, Affiliation, Pharmaceutical industry, Healthcare, Management, Medicare, Medicaid

FRAMINGHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH ), an industry leader in healthcare commercial intelligence, today introduced its Atlas Dataset, which provides the foundation for the company’s healthcare commercial intelligence and powers Definitive Healthcare’s existing products, analytics, and solutions.

Key Points: 
  • FRAMINGHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH ), an industry leader in healthcare commercial intelligence, today introduced its Atlas Dataset, which provides the foundation for the company’s healthcare commercial intelligence and powers Definitive Healthcare’s existing products, analytics, and solutions.
  • We’re excited to package up all the data that our clients know and love in the Atlas Dataset,” said Robert Musslewhite, CEO of Definitive Healthcare.
  • “With the Atlas Dataset, we’re empowering customers to make strategic data-driven decisions based on up-to-date intelligence on the complex and broad healthcare ecosystem.”
    Combining multiple datasets on more than 15 million healthcare experts and professionals and 300,000 healthcare organizations, the Atlas Dataset has multiple components, including:
    Atlas Reference & Affiliation provides clients with unique visibility into the operations of and connections between healthcare providers and healthcare organizations.
  • Powering the entire Atlas Dataset is the Definitive ID, a unique identifier assigned to every healthcare individual and organization that provides users with a standard way to navigate the healthcare ecosystem.

Origin Enters into Binding Letter of Intent with Safe Supply Streaming Co., a Pharmaceutical and Narcotics Investment Company with a First Mover Advantage in the Safe Supply Narcotics Sector

Retrieved on: 
Tuesday, January 31, 2023
Private, Canada Business Corporations Act, Columbia, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., United, ORIG, Special-purpose acquisition company, Cannabis, Health Canada, Government, Regulation, LOI, Canadian Securities Exchange, Private placement, Laboratory, Letter, Narcotic, Fentanyl, CSE, Movement, Issuer, Investment, Definitive, Transaction, Death, Fine chemical, Security (finance), Cryptocurrency

Having a publicly listed vehicle will provide Safe Supply with robust financial resources to fund its ambitious growth program.

Key Points: 
  • Having a publicly listed vehicle will provide Safe Supply with robust financial resources to fund its ambitious growth program.
  • Pursuant to the terms of the Letter of Intent with Safe Supply, Origin is prepared to lend up to $500,000 as interim financing to allow Safe Supply to execute upon its business plan.
  • The resulting issuer that will exist upon completion of the Transaction (the “Resulting Issuer”) will change its business to that of Safe Supply.
  • All information contained in this press release with respect to Safe Supply, its business, the market in which it operates and the Private Placement was supplied by Safe Supply for inclusion herein.

Neutra Executes LOI to Acquire Private Clinical Research Site Management Organization

Retrieved on: 
Monday, January 30, 2023
Health, SMOS, Receipt, Acquisition, Hospital, Mercury, OTC, Physician, EBITDA, Clinical trial, FDA, Completion, Investment, SMO, Alzheimer's disease, Definitive, Research, Letter, Pharmaceutical industry, Management, KATY, Neutra

KATY, TX, Jan. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neutra Corporation (OTC PINK:NTRR), an emerging health and wellness research and development company, today announced the execution of a binding letter of intent to acquire Mercury Clinical Research, a privately-owned site management organization (SMO) comprised of a network of physicians conducting clinical trials for top-tier pharmaceutical companies.

Key Points: 
  • KATY, TX, Jan. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neutra Corporation (OTC PINK:NTRR), an emerging health and wellness research and development company, today announced the execution of a binding letter of intent to acquire Mercury Clinical Research, a privately-owned site management organization (SMO) comprised of a network of physicians conducting clinical trials for top-tier pharmaceutical companies.
  • Neutra expects to fund the acquisition with a combination of cash and equity to provide the Company with the optimum financial flexibility in the future.
  • "We are very excited to take the first steps towards the addition of Mercury to the Neutra family,” said Sydney Jim, Neutra Chief Executive Officer.
  • In addition, SMOs also work with hospitals and private practices to provide alternative treatments available to help advance medicine.

Snakes & Lattes Inc. Provides Shareholders With a 2022 Year End Summary as Well as a Glimpse Ahead & Some Guidance for 2023

Retrieved on: 
Tuesday, January 17, 2023
EBITDA, OTC, Definitive, Calendar, Star Wars, History, News, FY, LEGO, Snakes and Lattes, Light, POP, Video game, Retail, Coffee, Snake, The Walt Disney Company

(Despite All Toronto locations being closed all of Jan and most of Feb 2022)

Key Points: 
  • (Despite All Toronto locations being closed all of Jan and most of Feb 2022)
    After two quarters in FY 2023, Snakes & Lattes can give guidance to shareholders that the company does anticipate another significant increase in revenues for FY 2023 ending June 30th, 2023.
  • Tempe broke all historical records for the company; bringing in over $3M for calendar 2022.
  • One of the major highlights for Snakes & Lattes in 2022 was winning the annual TAGIE awards held in Chicago.
  • In 2021, LEGO took the category, but this year, Snakes & Lattes proudly cemented itself as the winner of the Most Innovative Retailer of 2022.

Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference

Retrieved on: 
Sunday, January 8, 2023
Emergency Use Authorization, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Party, Infection, COVID-19, Partner, Novartis, EUA, Letter, DLL3, Molecular Partners, Definitive, Intellectual property, FDA, Therapy, Conference, DARPin, Pharmaceutical industry, CONCORD

Expression of DLL3 is low in healthy tissue but significantly increased in certain tumor types, providing an opportunity for selective targeting.

Key Points: 
  • Expression of DLL3 is low in healthy tissue but significantly increased in certain tumor types, providing an opportunity for selective targeting.
  • *
    Molecular Partners and Novartis signed a non-binding letter of intent to negotiate a Research Framework Agreement with a primary focus on emerging infectious global health threats.
  • Patrick Amstutz, CEO of Molecular Partners, will present at the 41st Annual JP Morgan Healthcare Conference on Wednesday, January 11 at 10:30 AM ET (4:30 PM CET).
  • A webcast will be accessible on the Molecular Partners website, under the Events tab .

Catheter Precision’s VIVO™ System Used in More Than 800 Procedures in Leading U.S. and European Hospitals

Retrieved on: 
Thursday, December 1, 2022
Cardiology, Surgery, Public Relations, Investor Relations, General Health, Health, Medical Devices, Communications, Health Technology, Special, Disease, Tripura Merger Agreement, AS, Common stock, Definitive, Security (finance), Cardiac electrophysiology, VIVO, Financial statement, Communication, NYSE American, Catheter, Patient, Workflow, Arrhythmia, Sumathi Best Television Current Reporting Award, WILL, Common, CE, FDA, COVID-19, ALL, COMMUNICATION, Private, RA, Anatomy, Hospital, Physician, NYSE, Amigo, Acquisition, AND, Exhibit, FORM, Public Sector Net Cash Requirement, Public–Private Investment Program for Legacy Assets, Sale, 8-K, Business, OR, Form 10-K, Plan, Medical device, Medical imaging, Holding company, Mergers and acquisitions, Shareholder

Catheter Precisions lead product, VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time.

Key Points: 
  • Catheter Precisions lead product, VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time.
  • Additionally, Catheter Precision is working toward a commercial launch of a vessel closure device, currently planned for the first half of 2023.
  • Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias.
  • It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.